Skip to main content
. Author manuscript; available in PMC: 2013 Feb 3.
Published in final edited form as: Phys Biol. 2012 Feb 3;9(1):016004. doi: 10.1088/1478-3975/9/1/016004

Figure 2.

Figure 2

Figure 2

Figure 2

Figure 2

(A) CTC counts from samples from adenocarcinoma and squamous carcinoma patients do not differ according to histologic subtype of lung cancer. (B) CTC counts for the whole patient population at early, middle and late timepoints with bar representing the median CTC count at the 3 time points. (C) during the natural history of stage IV NSCLC at early, middle, and late timepoints the frequency with which patients had a non-zero value for the CTC count appeared to increase. (D) Examples of serial blood draws on two patient types. The solid line represents a patient who had undetectable CTCs early in the course of the disease, then progressed and died 45 days after the last sample showed an increase in the CTC count. The dotted line represents a patient who maintained low CTC counts and remained alive at last follow-up 345 days after the 1 year timepoint of the study.